Hypercalcemia and bone resorption in malignancy

Research output: Contribution to journalReview articlepeer-review


Hypercalcemia is the most common paraneoplastic syndrome associated with cancer. This paper addresses the etiology and pathogenesis of hypercalcemia of malignancy and discusses the relative contributions of local and humoral effects on bone and renal calcium homeostasis. The roles of parathyroid hormone-related protein and other osteolytic cytokines are outlined. New biochemical markers that enable more specific monitoring of the response of bone metastases to treatment are introduced, including urinary excretion of the collagen crosslinks pyridinoline and deoxypyridinoline. The clinical management and prevention of hypercalcemia is systemically outlined, including indications for bisphosphonate, glucocorticoid, and calcitonin therapy. The results of recent trials of bisphosphonate therapy for the prevention of tumor progression and its subsequent problems such as bone pain, fracture, and hypercalcemia also are discussed.

Original languageEnglish
Pages (from-to)51-63
Number of pages13
JournalClinical Orthopaedics and Related Research
Issue number312
Publication statusPublished - Mar 1995


  • Animals
  • Bone Neoplasms
  • Breast Neoplasms
  • Cytokines
  • Diphosphonates
  • Disease Progression
  • Humans
  • Hypercalcemia
  • Osteolysis
  • Paraneoplastic Syndromes
  • Journal Article
  • Review


Dive into the research topics of 'Hypercalcemia and bone resorption in malignancy'. Together they form a unique fingerprint.

Cite this